5-Methylimidazo<2,1-b>thiazol | 51226-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并噻唑类
• 英文名称: 5-Methylimidazo<2,1-b>thiazol
• 英文别名: 5-methyl-imidazo[2,1-b]thiazole；5-Methylimidazo[2,1-b][1,3]thiazole
• CAS: 51226-35-8
• 化学式: C₆H₆N₂S
• 分子量: 138.193
• InChiKey: AIKXYYBTHCBEAY-UHFFFAOYSA-N

物化性质

• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  以 水 为溶剂， 反应 12.0h， 生成 5-Methylimidazo<2,1-b>thiazol
  参考文献：
  名称：

  Synthesis of Imidazo[1,2-a]pyridines: “Water-Mediated” Hydroamination and Silver-Catalyzed Aminooxygenation

  摘要：

  Aqueous syntheses of methylimidazo[1,2-a]pyridines without any deliberate addition of catalyst are reported. Imidazo[1,2-a]pyrazine and imidazo[2,1-a]isoquinoline were also obtained in good yields under similar conditions. With acetonitrile as solvent, Ag-catalyzed intra-molecular aminooxygenation produced imidazo[1,2-a]pyridine-3-carbaldehydes in moderate to good yields.

  DOI：

  10.1021/jo3025303

文献信息

• [EN] 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS<br/>[FR] COMPOSÉS 2-HÉTÉROCYCLYLAMINO PYRAZINES SUBSTITUÉES EN POSITION 6 EN TANT QU'INHIBITEURS DE CHK-1
  申请人：PFIZER

  公开号：WO2010016005A1

  公开（公告）日：2010-02-11

  The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.

  本发明涉及式(I)的化合物，及其药用可接受的盐，它们的合成以及它们作为CHK-1抑制剂的用途。
• [EN] MICROBICIDAL HETEROCYCLES<br/>[FR] HÉTÉROCYCLES MICROBICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2012069633A1

  公开（公告）日：2012-05-31

  Compounds of the formula I Formula (I) wherein the substituents are as defined in claim 1, are useful as active ingredients, which have microbiocidal activity, in particular fungicidal activity.

  式I的化合物，其中取代基如权利要求1所定义的那样，作为活性成分是有用的，具有微生物杀灭活性，特别是真菌杀灭活性。
• [EN] HETEROARYLS AND THEIR USE AS PI3K INHIBITORS<br/>[FR] HÉTÉROARYLES ET APPLICATIONS ASSOCIÉES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2010090716A1

  公开（公告）日：2010-08-12

  This invention provides compounds of formula (IA) or (IB): wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  这项发明提供了式（IA）或（IB）的化合物：其中R1、R2、G1和HY如规范中所述。这些化合物是PI3K和/或mTor的抑制剂，因此可用于治疗增殖性、炎症性或心血管疾病。
• [EN] 3-AZA-BICYCLO[3.3.0]OCTANE COMPOUNDS<br/>[FR] COMPOSÉS 3-AZA-BICYCLO[3.3.0]OCTANE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009004584A1

  公开（公告）日：2009-01-08

  The invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of the formula (I) wherein R1, R2, R3, and A are as described in the description and their use as orexin receptor antagonists.

  这项发明涉及式(I)的3-aza-bicyclo[3.3.0]辛烷衍生物，其中R1、R2、R3和A如描述中所述，并且它们作为促进睡眠的受体拮抗剂的用途。
• 2-AZA-BICYCLO[3.3.0]OCTANE DERIVATIVES
  申请人：Aissaoui Hamed

  公开号：US20110009461A1

  公开（公告）日：2011-01-13

  The invention relates to 2-aza-bicyclo[3.3.0]octane derivatives of Formula (I) wherein A, B, and R 1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

  这项发明涉及到式(I)中的2-aza-bicyclo[3.3.0]辛烷衍生物，其中A、B和R1如描述中所述，并且涉及到这些化合物的使用，或者这些化合物的药用盐的使用，作为药物，特别是作为促进睡眠的药物受体拮抗剂。

表征谱图